Company intelligence / Profile preview

NeuroKine Therapeutics

New York City, New York, United Statesneurokinetp.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 2

Overview

NeuroKine Therapeutics’ lead candidate MW150, a novel small molecule stress kinase inhibitor targeting p38α MAP kinase pathways implicated in neuroinflammation and neuronal dysfunction, has demonstrated efficacy in preclinical models of Alzheimer’s and other dementias. The company has completed FDA-recommended preclinical safety studies and initiated Phase 1 clinical trials to establish safety and support future efficacy studies in patients with Alzheimer’s disease. The approach targets mechanisms not addressed by current or late-stage AD drugs.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

mw150

Partnerships

Collaboration with Columbia University scientist for drug development

Beyond the preview

Go deeper on NeuroKine Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroKine Therapeutics.

Explore the full profile